mAb-AR20.5

a murine anti-MUC1 monoclonal antibody generated to induce MUC1 antigen-specific immune responses through the formation of immune complexes with circulating MUC1 and/or MUC1-expressing tumor cells that may target these immune complexes (IC) to receptors on dendritic cells (DCs)

Also Known As:

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Caffrey, Thomas C: 1 article (03/2018)
2.	Grunkemeyer, James A: 1 article (03/2018)
3.	Hollingsworth, Michael A: 1 article (03/2018)
4.	Madiyalakan, Ragupathy: 1 article (03/2018)
5.	Mehla, Kamiya: 1 article (03/2018)
6.	Nicodemus, Christopher F: 1 article (03/2018)
7.	O'Connell, Kelly A: 1 article (03/2018)
8.	Schultes, Birgit C: 1 article (03/2018)
9.	Singh, Pankaj K: 1 article (03/2018)
10.	Steele, Maria M: 1 article (03/2018)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2018 - "Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors." 03/01/2018 - "The current study explores a novel therapeutic combination wherein tumor-bearing hosts can be immunologically primed with their own antigen, through opsonization with a tumor antigen-targeted antibody, mAb-AR20.5. " 12/01/2004 - "BrevaRex mAb-AR20.5 is a murine anti-MUC1 monoclonal antibody generated to induce MUC1 antigen-specific immune responses through the formation of immune complexes with circulating MUC1 and/or MUC1-expressing tumor cells that may target these immune complexes (IC) to receptors on dendritic cells (DCs). "
2.	Hypersensitivity (Allergy) 12/01/2004 - "mAb-AR20.5 was well-tolerated, not associated with dose-limiting toxicity, and did not induce hypersensitivity reactions. "

Related Drugs and Biologics

1.	Antigens
2.	Neoplasm Antigens (Tumor Antigens)
3.	mAb-AR20.5
4.	Antigen-Antibody Complex (Immune Complex)
5.	Monoclonal Antibodies